PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30285125-3	2019	Design: The study was a randomized, placebo-controlled crossover trial where 10 healthy men received either infusion of beta2-agonist terbutaline (0.2 to 0.4 mg) or placebo.	Terbutaline	134-145	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	120-125